Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
Status:
Completed
Trial end date:
2020-06-27
Target enrollment:
Participant gender:
Summary
To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid
dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in
patients with DM who are known to have impaired response to clopidogrel therapy. Since DM
patients frequently require elective PCI due to chronic progression of CAD (and not solely
because of an acute thrombotic complication), and clopidogrel remains the guideline
recommended P2Y12 inhibiting therapy for these patients, understanding the PD effects of the
ticagrelor 60 mg bid regimen in this setting is an unmet clinical need. This is also in light
of the ongoing THEMIS trial which is specifically evaluating the impact of the ticagrelor 60
mg bid dosing regimen in type 2 DM patients without a prior major CV event.